PL3325443T3 - Sposób otrzymywania pridopidyny - Google Patents
Sposób otrzymywania pridopidynyInfo
- Publication number
- PL3325443T3 PL3325443T3 PL16828644.1T PL16828644T PL3325443T3 PL 3325443 T3 PL3325443 T3 PL 3325443T3 PL 16828644 T PL16828644 T PL 16828644T PL 3325443 T3 PL3325443 T3 PL 3325443T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidin
- obtaining
- obtaining pridopidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195756P | 2015-07-22 | 2015-07-22 | |
| PCT/US2016/043682 WO2017015609A1 (en) | 2015-07-22 | 2016-07-22 | Process for preparing pridopidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3325443T3 true PL3325443T3 (pl) | 2022-08-01 |
Family
ID=57834816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16828644.1T PL3325443T3 (pl) | 2015-07-22 | 2016-07-22 | Sposób otrzymywania pridopidyny |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10047049B2 (pl) |
| EP (1) | EP3325443B1 (pl) |
| AR (2) | AR105434A1 (pl) |
| CA (1) | CA2993607C (pl) |
| DK (1) | DK3325443T3 (pl) |
| ES (1) | ES2922991T3 (pl) |
| HU (1) | HUE059158T2 (pl) |
| PL (1) | PL3325443T3 (pl) |
| TW (1) | TW201718491A (pl) |
| WO (1) | WO2017015609A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9907786B2 (en) * | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| EP3357909A1 (en) * | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| EP4741013A3 (en) | 2020-02-13 | 2026-08-05 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| CA3250337A1 (en) | 2022-05-03 | 2023-11-09 | Prilenia Neurotherapeutics Ltd. | METHODS AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE |
| IL315049A (en) | 2024-08-15 | 2026-03-01 | Prilenia Neurotherapeutics Ltd | Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0641320T3 (da) | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MX2007004216A (es) | 2004-10-13 | 2007-10-10 | Neurosearch Sweden Ab | Proceso para la sintesis de 4-(3-sulfonil)-piperidinas. |
| ES2659577T3 (es) * | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX343620B (es) * | 2011-09-07 | 2016-11-11 | Teva Pharmaceuticals Int Gmbh | Forma polimorfica de clorhidrato de pridopidina. |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CA2937243C (en) | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
-
2016
- 2016-07-21 AR ARP160102219A patent/AR105434A1/es active IP Right Grant
- 2016-07-22 ES ES16828644T patent/ES2922991T3/es active Active
- 2016-07-22 US US15/217,683 patent/US10047049B2/en active Active
- 2016-07-22 WO PCT/US2016/043682 patent/WO2017015609A1/en not_active Ceased
- 2016-07-22 EP EP16828644.1A patent/EP3325443B1/en active Active
- 2016-07-22 TW TW105123329A patent/TW201718491A/zh unknown
- 2016-07-22 PL PL16828644.1T patent/PL3325443T3/pl unknown
- 2016-07-22 HU HUE16828644A patent/HUE059158T2/hu unknown
- 2016-07-22 DK DK16828644.1T patent/DK3325443T3/da active
- 2016-07-22 CA CA2993607A patent/CA2993607C/en active Active
-
2024
- 2024-08-14 AR ARP240102151A patent/AR133546A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170022158A1 (en) | 2017-01-26 |
| WO2017015609A1 (en) | 2017-01-26 |
| US10047049B2 (en) | 2018-08-14 |
| EP3325443A1 (en) | 2018-05-30 |
| CA2993607C (en) | 2024-01-16 |
| CA2993607A1 (en) | 2017-01-26 |
| TW201718491A (zh) | 2017-06-01 |
| HUE059158T2 (hu) | 2022-10-28 |
| EP3325443B1 (en) | 2022-06-08 |
| ES2922991T3 (es) | 2022-09-22 |
| EP3325443A4 (en) | 2019-01-16 |
| AR133546A2 (es) | 2025-10-08 |
| DK3325443T3 (da) | 2022-07-18 |
| AR105434A1 (es) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249981A0 (en) | Method | |
| PL3167096T3 (pl) | Dwuetapowy sposób nanoszenia | |
| PL4279535T3 (pl) | Sposoby wytwarzania polioli | |
| IL272851A (en) | Methods of using dipivefrin | |
| DK3294885T3 (da) | Fremgangsmåde til at fremstille rna | |
| HUE059158T2 (hu) | Eljárás pridopidin elõállítására | |
| JP2016208024A5 (ja) | 電極の作製方法 | |
| DK3341479T3 (da) | LNA-G-Proces | |
| PL4140976T3 (pl) | Sposób wytwarzania HCFO-1233ZD | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3283210T3 (da) | Fremgangsmåde | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| BR112016025413A2 (pt) | método de fabricação de um inserto e inserto | |
| DK3374495T3 (da) | Forbedrede fremgangsmåder til vævsfremstilling | |
| PL3630738T3 (pl) | Sposób wytwarzania ozanimodu | |
| DK3346990T3 (da) | Fremgangsmåde til stråleformaling | |
| DK3137449T3 (da) | Fremgangsmåder til fremstilling af substituerede cycloseriner | |
| FR3023290B1 (fr) | Derives de flavaglines | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| IL254502B (en) | Solid forms of menaquinols | |
| EP3338088A4 (en) | BIOMARKER FOR CORONARY DISEASE | |
| PL3589742T3 (pl) | Sposób wykrywania | |
| LT3280721T (lt) | Azoto iprito darinių gavimo būdas | |
| PL3256003T3 (pl) | Sposoby ekstrakcji lipidów | |
| LT3152325T (lt) | Trišakės neuralgijos diagnostikos būdas |